Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Change in Account Payables (2016 - 2025)

Apyx Medical (APYX) has disclosed Change in Account Payables for 15 consecutive years, with -$155000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 120.5% year-over-year to -$155000.0, compared with a TTM value of $355000.0 through Dec 2025, up 663.49%, and an annual FY2025 reading of $355000.0, up 663.49% over the prior year.
  • Change in Account Payables was -$155000.0 for Q4 2025 at Apyx Medical, down from $328000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $782000.0 in Q1 2021 and bottomed at -$776000.0 in Q1 2023.
  • Average Change in Account Payables over 5 years is $76900.0, with a median of $169000.0 recorded in 2022.
  • Peak annual rise in Change in Account Payables hit 792.86% in 2023, while the deepest fall reached 1421.57% in 2023.
  • Year by year, Change in Account Payables stood at -$401000.0 in 2021, then soared by 226.18% to $506000.0 in 2022, then increased by 26.09% to $638000.0 in 2023, then increased by 18.5% to $756000.0 in 2024, then tumbled by 120.5% to -$155000.0 in 2025.
  • Business Quant data shows Change in Account Payables for APYX at -$155000.0 in Q4 2025, $328000.0 in Q3 2025, and $513000.0 in Q2 2025.